Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
Pfizer
since
auto-detected in 271 stories
10 days ago
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more
These are the stocks posting the largest moves in midday trading.
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable to predict at this time."
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
Pfizer maintained its 2025 guidance but noted it does not include any impact of tariffs or trade policy, "which we are unable to predict at this time."
14 days ago
Trump pharma tariffs would raise U.S. drug costs by $51 billion annually, report finds
found
Pharmaceutical Research and Manufacturers of America includes Amgen, Bristol Myers Squibb, Eli Lilly, and Pfizer, among others.
25 days ago
Stocks making the biggest moves premarket: Apple, Nvidia, Goldman Sachs, Pfizer and more
These are the stocks posting the largest moves in premarket trading.
Pfizer scraps daily weight loss pill after liver injury in one patient
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of the booming market for GLP-1s.
Pfizer scraps daily weight loss pill after liver injury in one patient
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of the booming market for GLP-1s.